Focus Partners Wealth Acquires 34,466 Shares of Bristol-Myers Squibb (NYSE:BMY)

Focus Partners Wealth boosted its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 18.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 217,570 shares of the biopharmaceutical company's stock after buying an additional 34,466 shares during the period. Focus Partners Wealth's holdings in Bristol-Myers Squibb were worth $12,807,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BMY. Fairway Wealth LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $28,000. Transce3nd LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $28,000. Comprehensive Financial Planning Inc. PA bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $34,000. Westend Capital Management LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $38,000. Finally, Tacita Capital Inc bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $39,000. 76.41% of the stock is owned by institutional investors.

Analysts Set New Price Targets

BMY has been the subject of several recent research reports. Cantor Fitzgerald restated a "neutral" rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Piper Sandler initiated coverage on Bristol-Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective for the company. William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Citigroup lifted their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Finally, Argus raised Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Stock Performance

NYSE:BMY traded up $0.96 during trading on Friday, reaching $46.77. The company's stock had a trading volume of 12,103,063 shares, compared to its average volume of 13,252,337. The firm has a market cap of $95.18 billion, a price-to-earnings ratio of -10.58, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The firm has a 50 day moving average of $53.35 and a 200-day moving average of $56.01. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the prior year, the company earned ($4.40) EPS. The business's revenue for the quarter was down 5.6% on a year-over-year basis. Research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 5.30%. Bristol-Myers Squibb's dividend payout ratio (DPR) is 92.88%.

Insider Buying and Selling

In related news, EVP Samit Hirawat acquired 4,250 shares of the company's stock in a transaction that occurred on Friday, April 25th. The shares were acquired at an average price of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.